Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
about
Guidelines for the management of myeloproliferative neoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FNew Therapeutic Approaches in Polycythemia VeraManagement of polycythaemia vera: a critical review of current data.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Current and future treatment options for polycythemia vera.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart reviewJumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Rethinking the diagnostic criteria of polycythemia vera.Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Quality of life in MPN comes of age as a therapeutic target.Therapeutic apheresis for patients with cancer.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Anagrelide and Mutational Status in Essential Thrombocythemia.Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.
P2860
Q26778326-32DEE3C1-AAEC-4C8E-834C-63381FE52E43Q26795666-F14596EB-5217-4240-BC57-6356E8F5AC8DQ26795677-E276E420-4F24-43B1-9730-361D22BE9C0CQ31009757-68B72742-AEEB-478B-AFDF-8AC595D74F8FQ33411637-90E7378F-A914-4665-98CF-AEA13A71FF9CQ35572748-45C13C1E-3363-4718-9C31-2F4E6E2E26DDQ36311347-6F787949-0859-4AC5-B164-99F602E81472Q36529881-3AE04602-D113-4695-96A6-EF93CB03A990Q36816733-8888A0E4-9A85-4E2B-91E7-FA2FE6FED4F0Q37555790-6CA7BBD7-9150-4E19-9EE4-C4FF0CB59F84Q37561170-0C9BC28C-C152-4D6E-A987-2944239B88B5Q37636747-A7361AED-4718-4000-9CE3-5D288213C202Q37679175-8EC5A61B-C84D-4FFB-BB36-65EC043787F0Q38172388-33CBC269-0BEB-4D9E-8A6B-80DF63EBB447Q38187684-B233F5AE-DDCA-4354-90B9-EC1698F2158BQ38210664-8F46BA53-C7B3-49B6-A298-14FAF3F7D205Q38242725-BF49087A-0A38-42F2-A69B-3280D8D764CFQ38254893-C46A8B7D-57CA-48AD-AF51-FB2F63886564Q38287610-86EA751A-CCE0-47F4-9884-674C5F23D514Q38341625-FB4C67FA-C495-4DED-A25D-3750C7FC8C22Q38393343-2643CEE9-9EBB-4894-BA6D-4019E503A2E9Q38646051-FE195793-D61A-4C4D-B9F6-D254A3EBC779Q38740700-CEFEBD92-5333-45CD-9C00-B304005D258DQ38742500-C19E6F1C-FDDE-4151-A3A3-6F0C69E12F1AQ38812599-3EE8F98A-1582-4591-8F13-C71D406F9141Q38909050-2FF4299D-573C-4BB1-9AB6-E6320603BE92Q39041471-DFA30542-4EE1-4FE2-9883-89C59F4F4D4AQ39867043-5162D8F6-D6FB-49C6-AD0B-B51ED774CCDBQ39869975-3C40EB27-32B4-46EF-B01E-086FEFFED61CQ41095829-49D21E6B-69FA-4B4A-8940-06B2FCC63A8AQ41160178-A3541CEF-3947-4894-9E11-977426870CD2Q42609605-B28E4DD7-4CEB-434C-8EF0-DEE01CF71E9CQ42702330-88461ED2-532F-470C-8AFE-6D711D56C4D4Q42760638-1B4FDEE4-92EA-4583-B391-097A6B89A442Q46525156-0A36D30E-25BA-4745-BE1B-25583E0C86DEQ50449411-D7A7A123-03A6-4F6F-971B-4AD0DDAC079EQ51608068-6E97CB3C-4C13-4BEE-8CD9-8B51077ADAA1Q54262553-9D08470E-7543-4DB4-8731-36FC155BB73AQ54341051-9D98E471-58BC-4784-A936-12B635CA3180Q54357496-C9CF486A-507A-410C-890F-830FAA8E8780
P2860
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Revised response criteria for ...... and IWG-MRT consensus project.
@en
type
label
Revised response criteria for ...... and IWG-MRT consensus project.
@en
prefLabel
Revised response criteria for ...... and IWG-MRT consensus project.
@en
P2093
P2860
P50
P1433
P1476
Revised response criteria for ...... and IWG-MRT consensus project
@en
P2093
Alessandro M Vannucchi
Animesh Pardanani
Ayalew Tefferi
Carlos Besses
Claire Harrison
Eva Lengfelder
Francisco Cervantes
Giovanni Barosi
Guido Finazzi
Heinz Gisslinger
P2860
P304
P356
10.1182/BLOOD-2013-01-478891
P407
P577
2013-04-16T00:00:00Z